

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Application No.: 10/088,814

Filing Date: March 21, 2002

Inventor: Mortlock et al.

For: Quinazoline Derivatives and Their Use
as Pharmaceuticals

Attorney Docket No. ASZD-P01-599

Group Art Unit: N/A

Examiner: Steven Post

I hereby certify that this correspondence is being facsimile transmitted to the Patent and Trademark Office, facsimile no. 703-746-9195, on the date shown below.

Dated: 11/15/02 Signature: Maura A. Gallagher

CHANGE OF ATTORNEY DOCKET NUMBER


Assistant Commissioner for Patents
Washington, DC 20231

Dear Sir:

Please note that the Attorney Docket Number has been changed from
P 279455 to ASZD-P01-599. Please reference ASZD-P01-599 on all future correspondence.

Respectfully submitted,

ROPES AND GRAY

By 

David P. Halstead

Registration No.: 44,735

Telephone: (617) 951-7615

Facsimile: (617) 951-7050

Boston, Massachusetts 02110

Dated: November 15, 2002

5991845.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**REVOCATION OF PRIOR POWERS OF ATTORNEY AND
APPOINTMENT OF NEW POWER OF ATTORNEY OR AUTHORIZATION OF
AGENTS**

Commissioner for Patents
Washington, DC 20231

Sir:

Syngenta Limited (formerly Zeneca Limited), Zeneca Pharma S.A., AstraZeneca UK Limited, and AstraZeneca AB hereby revoke, as appropriate, all previous powers of attorney and authorizations of agent previously granted for the following U.S. patent applications:

Patent Number	Date of Revocation	Patent Number	Date of Revocation
08/860248	06/24/97	6034056	03/07/00
09/381836	09/24/99	6251913	06/26/01
09/554224	07/11/00	6344570	02/05/02
09/463452	01/27/00	6372734	04/16/02
09/426859	10/26/99		
09/463324	01/24/00		
09/463844	02/01/00		
09/581909	06/19/00		
09/594119	06/14/00		
09/626378	07/26/00		
09/673465	10/17/00		
09/719283	12/11/00		
09/733956	06/01/01		
09/744329	01/23/01		
09/744331	01/23/01		
09/763598	02/26/01		
09/763709	02/26/01		
09/786702	03/07/01		
09/788687	02/21/01		
09/814119	03/22/01		
09/831143	06/25/01		

Patent No.	Patent No.	Patent No.	Patent No.
09/831290	05/08/01		
09/883489	06/19/01		
09/889493	07/02/01		
09/889494	09/12/01		
09/889515	10/10/01		
09/889516	10/02/01		
09/913069	11/15/01		
10/101948	03/21/02		
10/088814	03/21/02		
10/088854	03/21/02		
10/088852	03/21/02		
10/088856	03/21/02		
60/330588	10/25/01		
60/330589	10/25/01		

The following attorneys or agents of the Patent Group at Ropes & Gray, and all other attorneys or agents affiliated with Customer No.:



28120

are hereby appointed to prosecute applications and transact all business in the United States Patent and Trademark Office for the above applications:

Madeline F. Baer	36,437	Christopher Natkanski	50,365
Steven Baglio	P-51,426	John D. Quisel	47,874
J. Steven Baughman	47,414	Spencer H. Schneider	45,923
Mark W. Bellomy	P-51,452	Sanjay Sitlani	48,489
Johnny Y. Chen	46,614	Wolfgang E. Stutius	40,256
Gregory Glover	34,173	Anita Varma	43,221
William G. Gosz	27,787	Matthew P. Vincent	36,709
Patricia Granahan	32,227	Dalila Arguez	P-52,351
David P. Halstead	44,735	Agnes S. Lee	46,862
Daniel Hansburg	36,156	Paul E. Lewkowicz	44,870
Edward J. Kelly	38,936	Yu Lu	50,306
Charles Larsen	48,533	Robert A. Mazzaresse	42,852

Please change the correspondence address for to the above-identified application
to:

Patent Group
Ropes & Gray
One International Place
Boston, MA 02110

The undersigned, whose title is supplied below, is empowered to sign this
Revocation and New Power of Attorney on behalf of the Assignee.

Respectfully submitted,



Officer

22 October 2002

Date

Kevin Bill

Print or Type Name of Person Signing

Patent Director

Title

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Mortlock et al.

Application No./Patent No.: 10/088814

Filed/Issue Date: March 21, 2002

Entitled: QUINAZOLINE DERIVATIVES AND THEIR USE A PHARMACEUTICALS

AstraZeneca AB
(Name of Assignee)

, a

Corporation

Type of Assignee, e.g., corporation, partnership, university, government agency, etc.

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by, percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A. ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 013007 Frame 0097 , or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____ , Frame _____ , or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____ , Frame _____ , or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____ , Frame _____ , or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

- ☐ Copies of assignments or other documents in the chain of title are attached.
(NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08)

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

22 October 2002
Date

Kevin Bill

Typed or printed name

Kevin Bill
Signature

Patent Director

Title